Výsledky vyhledávání - "Kathleen Martyn"

Abstract 5455: Nuclear export inhibitor selinexor synergizes with proteasome inhibitor marizomib in preclinical models of glioblastoma

Autor: Hua Chang, Leah Henegar, Christopher J. Walker, Trinayan Kashyap, Marie Maloof, Feng Wang, Kathleen Martyn, Shira Orr, Sharon Tamir, Michael G. Kauffman, Sharon Shacham, Yosef Landesman

Publikováno v: Cancer Research. 82:5455-5455

Background: Glioblastoma (GBM) is an aggressive brain cancer with poor prognosis and limited treatment options. Selinexor is a first-in-class oral inhibitor of Exportin 1 (XPO1/CRM1) with broad anti-cancer activities and is clinically approved to tre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bae542ffb51a7eefc5dc5fc842ca15f7
https://doi.org/10.1158/1538-7445.am2022-5455

Zobrazit plný text záznamu

Abstract 6022: Synergistic anti-cancer effects of selinexor and bevacizumab in mouse xenograft models of glioblastoma

Autor: Leah Henegar, Hua Chang, Christopher J. Walker, Trinayan Kashyap, Marie Maloof, Feng Wang, Kathleen Martyn, Shira Orr, Sharon Tamir, Michael G. Kauffman, Sharon Shacham, Yosef Landesman

Publikováno v: Cancer Research. 82:6022-6022

Background: Glioblastoma (GBM) is the most common primary brain tumor with a poor prognosis. It is also one of the most vascularized human tumors. The anti-angiogenesis agent bevacizumab (BEV) is the only US FDA approved agent for recurrent GBM. Give

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::db8190124eab86cc5e37bd7e535ffad7
https://doi.org/10.1158/1538-7445.am2022-6022

Zobrazit plný text záznamu

Abstract 5519: Selinexor synergizes with anti-PD-1 antibody and inhibits tumor growth and metastasis in syngeneic mouse models of KRAS mutant colorectal cancer

Autor: Hua Chang, Leah Henegar, Christopher J. Walker, Trinayan Kashyap, Marie Maloof, Feng Wang, Kathleen Martyn, Shira Orr, Michael G. Kauffman, Sharon Shacham, Yosef Landesman

Publikováno v: Cancer Research. 82:5519-5519

Background: Colorectal cancer (CRC) is the second leading cause of cancer related death. In approximately half of all CRC cases, oncogenic KRAS mutations underlie poor prognosis and drug resistance. A previous multi-genomic analysis of 4,725 biologic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a86a5ed041c5990844864a89541bbfed
https://doi.org/10.1158/1538-7445.am2022-5519

Zobrazit plný text záznamu

Abstract 6023: Selinexor synergizes with temozolomide in preclinical models of glioblastoma independent of MGMT promoter methylation

Autor: Leah Henegar, Hua Chang, Christopher J. Walker, Trinayan Kashyap, Marie Maloof, Feng Wang, Kathleen Martyn, Shira Orr, Sharon Tamir, Michael G. Kauffman, Sharon Shacham, Yosef Landesman

Publikováno v: Cancer Research. 82:6023-6023

Background: The alkylating agent temozolomide (TMZ) is widely applied as an effective first line treatment to glioblastoma (GBM), but its effectiveness is substantially reduced by the MGMT O6-methylguanine-DNA methyltransferase that repairs the main

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d2661930ce1bc6324e2e43e41813ef59
https://doi.org/10.1158/1538-7445.am2022-6023

Zobrazit plný text záznamu

Abstract 1049: Optimizing the treatment schedule of selinexor in combination with decitabine in AML

Autor: Sharon Shacham, Yosef Landesman, Leah Henegar, Kathleen Martyn, Christopher James Walker, Hua Chang, Trinayan Kashyap, Nicholas Fredette

Publikováno v: Cancer Research. 81:1049-1049

Background: Decitabine (DEC) is a hypomethylating agent approved to treat acute myeloid leukemia (AML) that can reactivate tumor suppressor genes that are epigenetically silenced by DNA methylation. Selinexor (SEL) is a selective inhibitor of nuclear

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9f6cc1839d0df9f0615303a774a0c820
https://doi.org/10.1158/1538-7445.am2021-1049

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání